AstraZeneca Pharma India Limited (ASTRAZEN) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

AstraZeneca Pharma India Limited continues to navigate a high-growth phase as it expands its oncology and rare disease portfolios within the competitive Indian pharmaceutical market. Investors will be looking for clarity on how the company is managing significant rupee-driven import cost pressures alongside a major leadership transition in its senior management team.

AstraZeneca Pharma India Limited Q1 Results Date and Time

The board meeting is scheduled for August 10, 2026, to consider the audited financial results and recommend dividend for FY2026.

The company has already communicated to shareholders regarding a final dividend of Rs. 36 per share for FY 2025-26, with a record date of July 31, 2026.

What to expect from AstraZeneca Pharma India Limited's Q1 FY27 results

AstraZeneca is expected to maintain revenue growth ahead of the broader IPM, supported by a strong sector-wide tailwind and the recent launch of new products including Enhertu and Fasenra. However, the company faces a material FX headwind as the rupee depreciated approximately 10.5% YoY to an average of Rs. 94.6/USD in Q1 FY27, which impacts its 72.9% import-heavy procurement model. Management will likely address the impact of this currency volatility on gross margins, which were previously compressed to 40% in FY25, while also clarifying the financial implications of the Rs. 148.66 crore NPPA demand notice received in late July 2026. The upcoming call will also be a key venue for management to provide updates on operational continuity following the resignation of CFO Bhavana Agrawal and the departure of four other senior leaders during the quarter.

Key Things To Watch

Revenue growth and new product uptake: Tracking momentum against the Q1 FY26 base of Rs. 526.31 crore.

• Assessment of revenue contribution from new CDSCO approvals including Enhertu for HER2-positive breast cancer and Fasenra for HES.
• Management commentary on the sustainability of the 32.6% revenue growth rate achieved in FY26.

Gross margin and FX impact: Evaluating the bridge between import costs and product mix shifts.

• Quantification of the impact of the ~10.5% YoY rupee depreciation on procurement costs from AstraZeneca UK and Sweden.
• Updates on potential margin recovery following the manufacturing exit at the Yelahanka site.

Regulatory and legal developments: Monitoring the status of recent NPPA and tax demands.

• Clarification on whether the Rs. 148.66 crore Symbicort and Rs. 0.80 crore Betaloc demands are treated as provisions or contingent liabilities.
• Status of the company's legal strategy regarding the Rs. 9.24 crore GST appeal for FY 2018-19.

Management transition: Assessing operational continuity amid senior leadership changes.

• Update on CFO succession planning following the resignation of Ms. Bhavana Agrawal effective August 31, 2026.
• Introduction of new senior appointees including the Director of Commercial Excellence and Director of Oncology.